Journal article

Melasma like hyperpigmentation on face: A rare side effect of imatinib

AGAnusha Gupta AGAnusha Gupta SKSunil Kumar SKSunil Kumar SCSaurav Chaturvedi SCSaurav Chaturvedi ANApoorva Nirmal ANApoorva Nirmal
Year0
Volume5
Issue2
Pages79-80

Abstract

Imatinib mesylate is a cytotoxic agent that is used in chronic myeloid leukaemia. Common reported side effect is hypopigmentation; here we report a 48 year old female who developed hyperpigmentation as melasma on her face while taking imatinib mesylate in a dose of 400 mg daily for chronic myeloid leukaemia.

Keywords: Drug-induced pigmentation, Imatinib-mesylate, Melasma, Chronic myeloid leukemia.

Cite this article

Citation data